ISCO on OTC

International Stem Cell CORP

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with BioAge Labs, Inc., Praxis Precision Medicines, Inc. or PROTHENA CORP PUBLIC LTD CO, or pick any stock.

  • TickerISCO on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address9745 Businesspark Avenue, San Diego, Ca 921312
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

International Stem Cell Corporation (sometimes referred to herein as “ISCO”, the “Company”, “we”, “us”, or “our”) is a clinical stage biotechnology company focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities and two revenue-generating businesses offering potential for increased future revenue.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-2.9%Operating margin4
-4.6%Net margin4
0.2%Revenue growth, 20254
-$35.0KFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Biomedical Market brought in 88% of the revenue International Stem Cell CORP broke down this way in fiscal 2025.

  1. Biomedical Market$8.5M488%up 3% from 2024
  2. Anti Aging Market$598.0K46%down 25% from 2024
  3. Anti Aging Skincare Market$598.0K46%down 25% from 2024
Business segments by year
Business segments20242025
Biomedical Market$8.3M$8.5M
Anti Aging Market$795.0K$598.0K
Anti Aging Skincare Market$795.0K$598.0K

Regions

United States brought in 86% of the revenue International Stem Cell CORP broke down this way in fiscal 2025.

  1. United States$7.8M486%up 1% from 2024
  2. Asia$719.0K48%down 19% from 2024
  3. Europe$448.0K45%up 10% from 2024
  4. Other Regions$95.0K41%up 56% from 2024
Regions by year
Regions20242025
United States$7.7M$7.8M
Asia$890.0K$719.0K
Europe$407.0K$448.0K
Other Regions$61.0K$95.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue44¢$4.0M
  • Research and development8¢$684.0K
  • Other costs47¢$4.2M
  • Interest2¢$151.0K

Out of $9.1M in revenue.4 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending100¢$43.0K

Out of $8.0K of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.4

Financial statements

Revenue567894$9.1M in 2025−4% since 2019
0$2.5M$5.0M$7.5M$10.0M2019: $9.5M$9.5M20192020: $7.1M$7.1M2020−25%2021: $7.2M$7.2M2021+1%2022: $8.2M$8.2M2022+14%2023: $7.8M$7.8M2023−5%2024: $9.1M$9.1M2024+17%2025: $9.1M$9.1M2025+0%
Operating income567894-$267.0K in 2025−95% since 2019
-$6.0M-$4.0M-$2.0M02019: -$5.7M-$5.7M20192020: -$2.8M-$2.8M2020−51%2021: -$1.9M-$1.9M2021−32%2022: -$183.0K-$183.0K2022−90%2023: -$663.0K-$663.0K2023+262%2024: -$68.0K-$68.0K2024−90%2025: -$267.0K-$267.0K2025+293%
Net income567894-$418.0K in 2025−90% since 2019
-$6.0M-$4.0M-$2.0M02019: -$4.3M-$4.3M20192020: -$2.7M-$2.7M2020−36%2021: -$899.0K-$899.0K2021−67%2022: -$331.0K-$331.0K2022−63%2023: -$131.0K-$131.0K2023−60%2024: -$209.0K-$209.0K2024+60%2025: -$418.0K-$418.0K2025+100%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Product sales$9.1M$9.1M
Cost of sales$4.0M$3.8M
General and administrative$3.5M$3.5M
Selling and marketing$1.1M$1.2M
Research and development$684.0K$657.0K
Total operating expenses$9.4M$9.2M
Loss from operations-$267.0K-$68.0K
Interest expense-$6.0K-$7.0K
Interest expense - related party-$145.0K-$138.0K
Other income, net$4.0K
Other expense, net-$151.0K-$141.0K
Net loss-$418.0K-$209.0K
Net loss per common share, basic-$0.05-$0.03
Net loss per common share, diluted-$0.05-$0.03
Weighted-average common shares used to compute net loss per share, basic8.0M shares8.0M shares
Weighted-average common shares used to compute net loss per share, diluted8.0M shares8.0M shares

Compare International Stem Cell CORP with another company

Leadership

Who has led International Stem Cell CORP, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Timothy P. Halter2006
  2. Jeff Krstich2007
  3. Kenneth C. Aldrich2008–2009
  4. Andrei Semechkin2009–2023
  5. Rouslan Semechkin2012

Chair

  1. Timothy P. Halter2006
  2. Kenneth C. Aldrich2007–2009

President

  1. Jeffrey Janus2007–2008
  2. Brian Lundstrom2009–2010
  3. Kurt Andrew May2011

Chief financial officer

  1. Timothy P. Halter2006
  2. William B. Adams2007–2009
  3. Edmund R. Wood2010–2011
  4. Tibor Jay Novak2013–2014
  5. Mahnaz Ebrahimi2015–2017
  6. Jennifer Stephens2017

Chief operating officer

  1. Kurt Andrew May2011
2010201520202025
Board members and other officers (16)

Former names

  • BTHC III INC.Apr 4, 2006 to Jan 19, 20072

Timeline

  1. Jan 17, 2012New chief executive Rouslan Semechkin becomes CEO12
  2. Dec 15, 2009New chief executive Andrei Semechkin becomes CEO13
  3. Apr 24, 2008New chief executive Kenneth C. Aldrich becomes CEO14
  4. Jan 3, 2007New chief executive Jeff Krstich becomes CEO15
  5. Jun 8, 2006New chief executive Timothy P. Halter becomes CEO16

Filings

68 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 17 major events, 17 insider forms, 14 other. The latest 20:

  1. Sep 17, 20264 EDGAR
  2. Sep 15, 20264 EDGAR
  3. Sep 11, 2026144 EDGAR
  4. Sep 8, 20268-K EDGAR
  5. Aug 13, 202610-Q EDGAR
  6. Aug 4, 2026DEF 14C DEFINITIVE INFORMATION STATEMENT EDGAR
  7. Jul 24, 2026PRE 14C PRELIMINARY INFORMATION STATEMENT EDGAR
  8. Jul 16, 20268-K CURRENT REPORT EDGAR
  9. Jun 23, 20264 EDGAR
  10. Jun 23, 20264 EDGAR
  11. Jun 12, 20268-K CURRENT REPORT EDGAR
  12. May 14, 202610-Q EDGAR
  13. Apr 29, 2026ARS EDGAR
  14. Apr 29, 2026DEF 14A EDGAR
  15. Mar 30, 202610-K EDGAR
  16. Nov 18, 20258-K CURRENT REPORT EDGAR
  17. Nov 13, 202510-Q EDGAR
  18. Sep 16, 20258-K CURRENT REPORT EDGAR
  19. Aug 14, 202510-Q EDGAR
  20. Jun 20, 20254 EDGAR

The 68 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 11, 2026MAIER PAUL VDirectorSale32,802$0.32$10.5KForm 4

From Forms 4 filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41